Mini Das (left) and Jingcheng Yuan at the University of Houston have shown how to combine X-ray attenuation, differential phase-contrast and dark field imaging in a single shot by appropriately positioning a mask (in front of a sample)…
LONDON — The rabble of journalists loitering in the mix zone near the Elland Road dressing rooms knew something was afoot when they saw Egyptian footballer Mohamed Salah walking toward them.
In almost nine years as Liverpool FC’s…
1 Industry-leading execution demonstrated by safety history. Our workforce Lost-Time Incident Rate for 2020-2024 was 0.02 per 200,000 work hours , based on full-year performance data. Performance data may include rounding. Incidents include injuries and illnesses. ExxonMobil workforce includes employees, contractors, and recent acquisitions (Denbury data beginning November 2, 2023, and Pioneer data beginning May 3, 2024). Industry benchmark: International Association of Oil & Gas Producers (IOGP) safety performance indicators and American Fuel & Petrochemical Manufacturers (AFPM) Report of Occupational Injuries and Illnesses are the Upstream and Downstream industry benchmarks, respectively. See publicly available industry data for industry peer comparators Chevron, Shell, and TotalEnergies reported on a per million hour work basis and converted to 200,000 work hour basis for comparison. Industry-leading execution further defined by Global Projects. ExxonMobil analysis of projects funded since formation of ExxonMobil Global Projects organization in 2019 using historical benchmarking results from Independent Project Analysis (IPA). Industry-leading cost management defined as cumulative structural cost savings since 2019 when compared to all other IOCs combined, based on publicly available data.
2 Leading total shareholder returns for the 5-year period from 12/1/2020 versus each IOC, as of 12/1/2025. Sourced from FactSet.
3 Earnings growth at constant prices and margins and Cash flow growth at constant prices and margins each exclude identified items and are adjusted to 2024 $65/bbl real Brent (assumes annual inflation of 2.5%) and 10-year average Energy, Chemical, and Specialty Product margins, which refer to the average of annual margins from 2010-2019. For clarity, cash flow from operations also excludes identified items, and working capital/other. See reconciliations on page 39 and page 40.
4 Return on capital employed is adjusted to 2024 $65/bbl real Brent (assumes annual inflation of 2.5%) and 10-year average Energy, Chemical, and Specialty Product margins, which refer to the average of annual margins from 2010-2019. It also assumes a $5 billion minimum cash balance. See definition on page 48.
5 Refers to percentage of production from advantaged assets (see definition on page 45).
6 Intensity is calculated as emissions per metric ton of throughput/production. ExxonMobil reported emissions, reductions, and avoidance performance data are based on a combination of measured and estimated emissions data using reasonable efforts and collection methods. Calculations are based on industry standards and best practices, including guidance from the American Petroleum Institute (API) and Ipieca. There is uncertainty associated with the emissions, reductions, and avoidance performance data due to variation in the processes and operations, the availability of sufficient data, quality of those data, and methodology used for measurement and estimation. Performance data may include rounding. Changes to the performance data may be reported as part of the Company’s annual publications as new or updated data and/or emission methodologies become available. We are working to continuously improve our performance and methods to detect, measure and address greenhouse gas emissions. ExxonMobil works with industry, including API and Ipieca, to improve emission factors and methodologies, including measurements and estimates. ExxonMobil’s plans regarding expected GHG emissions reductions by 2030 can be found in our 2025 Advancing Climate Solutions report.
The launch of a new batch of SpaceX Starlink satellites lit up the predawn sky in southern California today (Dec. 10) as the company marked its 160th flight of a Falcon 9 rocket this year.
Malin Akerman is lending her voice to tell a new story from The Hunting Wives author May Cobb.
Akerman, who stars in the series adaptation of The Hunting Wives, has joined the audiobook production of Cobb’s upcoming novel, All the…
SAVE $250: As of Dec. 10, the Apple Watch Ultra 2 (49mm, GPS + Cellular) has dropped to a new all-time low price of $549 at Amazon. That’s 31% or $250 off its list price of $799.
…
Observations of the formation of light-nuclei from high-energy collisions may help in the hunt for dark matter
Particle collisions at the Large Hadron Collider (LHC) can reach temperatures over one hundred thousand…
Humans mastered the art of creating fire 400,000 years ago, almost 350,000 years earlier than previously known, according to a groundbreaking discovery in a field in Suffolk.
It is known that humans used natural fire more than 1m years ago, but…
Wednesday, December 10, 2025
Sherlock-Lung study researchers use large-scale multi-omics analysis to identify biomarker of aggressive lung tumors.
Using lung cancer biospecimens from the Sherlock-Lung study, an international team led by National Institutes of Health (NIH) researchers, identified key factors that drive tumor evolution and influence outcomes. Overall, the findings, published Dec. 10, 2025, in Nature, describe a previously unknown origin of some aggressive lung cancers.
From whole-genome sequencing of more than 1,000 lung cancer cases, the team focused on 542 lung adenocarcinomas with diverse clonal architectures. Among them were a collection of aggressive tumors enriched with the ID2 mutational signature, characterized by a single base pair deletion. Surprisingly, this signature was associated with a type of mobile DNA known as LINE-1 (L1), an ancient part of the human genome that has the potential to wreak havoc by inserting many copies of itself in different places across the genome. L1 is typically silenced within a normal cell but in these tumors was reactivated. L1 reactivation could explain the rapid evolution and aggressiveness of this subgroup.
“It’s not every day that you discover a new mechanism for aggressive lung tumors,” said lead author Dr. Tongwu Zhang, Ph.D., Earl Stadtman investigator at NIH’s National Cancer Institute (NCI). “The finding underscores the power of whole-genome sequencing data to reveal genomic structural variants with significance for tumorigenesis.”
In addition, the investigators discovered that major driver gene mutations are responsible for varying tumor evolutionary trajectories. Tumors harboring KRAS mutations, which are more frequent in smokers, showed signs of rapid clonal evolution, which helps to explain the aggressive nature of these malignancies. In contrast, tumors enriched with EGFR mutations—more common in people who never smoked—had more sub-clonal architecture, which explains a more prolonged evolutionary course.
“The slow progression of EGFR-mutant tumors may allow for early detection and benefit from combination treatments to delay or prevent resistance,” said Maria Teresa Landi, M.D., Ph.D., senior investigator, NCI and manuscript’s senior author. “KRAS-mutant tumors and tumors enriched with the ID2 signature, which evolve quickly, may require more targeted approaches.”
This analysis was led by NIH/NCI, in collaboration with researchers from the Istituto Nazionale di Ricovero e Cura per Anziani (INRCA), Ancona, Italy; the University of Manchester, United Kingdom; Harvard University; the University of California San Diego; the University of Chicago; and over 40 additional international research centers.
About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of people with cancer. NCI supports a wide range of cancer research and training extramurally through grants and contracts. NCI’s intramural research program conducts innovative, transdisciplinary basic, translational, clinical, and epidemiological research on the causes of cancer, avenues for prevention, risk prediction, early detection, and treatment, including research at the NIH Clinical Center—the world’s largest research hospital. For more information about cancer, please visit the NCI website at https://www.cancer.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH…Turning Discovery Into Health®
Zhang T, et al. Uncovering the role of LINE-1 in the evolution of lung adenocarcinoma. Nature. 2025. DOI: 10.1038/s41586-025-09825-y. https://www.nature.com/articles/s41586-025-09825-y